Literature DB >> 21988294

The peripheral CD138+ population but not the CD138- population contains myeloma clonogenic cells in plasma cell leukaemia patients.

David Chiron, Sylvanie Surget, Sophie Maïga, Régis Bataille, Philippe Moreau, Steven Le Gouill, Martine Amiot, Catherine Pellat-Deceunynck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21988294     DOI： 10.1111/j.1365-2141.2011.08904.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  12 in total

1.  p53 regulates CD46 expression and measles virus infection in myeloma cells.

Authors:  Anne Lok; Geraldine Descamps; Benoit Tessoulin; David Chiron; Marion Eveillard; Catherine Godon; Yannick Le Bris; Astrid Vabret; Celine Bellanger; Laurent Maillet; Sophie Barillé-Nion; Marc Gregoire; Jean-François Fonteneau; Steven Le Gouill; Philippe Moreau; Frederic Tangy; Martine Amiot; Agnes Moreau-Aubry; Catherine Pellat-Deceunynck
Journal:  Blood Adv       Date:  2018-12-11

2.  Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.

Authors:  Caroline Rousseau; Ludovic Ferrer; Stéphane Supiot; Manuel Bardiès; François Davodeau; Alain Faivre-Chauvet; Pierre Baumgartner; John Wijdenes; Marie Lacombe; Jacques Barbet; Thierry Guillaume; Philippe Moreau; Jean Luc Harousseau; Françoise Kraeber-Bodéré; Michel Cherel
Journal:  Tumour Biol       Date:  2012-03-03

3.  Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions.

Authors:  Jianguo Wen; Wenjing Tao; Isere Kuiatse; Pei Lin; Yongdong Feng; Richard J Jones; Robert Z Orlowski; Youli Zu
Journal:  Int J Cancer       Date:  2014-07-23       Impact factor: 7.396

Review 4.  Molecular pathogenesis of multiple myeloma and its premalignant precursor.

Authors:  W Michael Kuehl; P Leif Bergsagel
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

5.  Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells.

Authors:  D Chiron; S Maïga; S Surget; G Descamps; P Gomez-Bougie; S Traore; N Robillard; P Moreau; S Le Gouill; R Bataille; M Amiot; C Pellat-Deceunynck
Journal:  Blood Cancer J       Date:  2013-06-07       Impact factor: 11.037

6.  Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.

Authors:  Alboukadel Kassambara; Dirk Hose; Jérôme Moreaux; Thierry Rème; Jennifer Torrent; Jean François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

7.  Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.

Authors:  Teresa Paíno; María E Sarasquete; Bruno Paiva; Patryk Krzeminski; Laura San-Segundo; Luis A Corchete; Alba Redondo; Mercedes Garayoa; Ramón García-Sanz; Norma C Gutiérrez; Enrique M Ocio; Jesús F San-Miguel
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

8.  RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.

Authors:  Sylvanie Surget; Géraldine Descamps; Carole Brosseau; Vincent Normant; Sophie Maïga; Patricia Gomez-Bougie; Nadège Gouy-Colin; Catherine Godon; Marie C Béné; Philippe Moreau; Steven Le Gouill; Martine Amiot; Catherine Pellat-Deceunynck
Journal:  BMC Cancer       Date:  2014-06-14       Impact factor: 4.430

9.  Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.

Authors:  Alboukadel Kassambara; Matthieu Schoenhals; Jérôme Moreaux; Jean-Luc Veyrune; Thierry Rème; Hartmut Goldschmidt; Dirk Hose; Bernard Klein
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

10.  Lack of BRAF V600E mutation in human myeloma cell lines established from myeloma patients with extramedullary disease.

Authors:  L Lodé; P Moreau; A Ménard; C Godon; C Touzeau; M Amiot; S Le Gouill; M C Béné; C Pellat-Deceunynck
Journal:  Blood Cancer J       Date:  2013-11-22       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.